Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose levetiracetam for cognitive function in early-onset Alzheimer's disease
TCTR20260903010Phase 2Not yet recruiting
- Sponsor
- Neurological Society of Thailand
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of levetiracetam in early-onset Alzheimer's disease (EOAD), sponsored by Neurological Society of Thailand. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
levetiracetam
03
Conditions
early-onset Alzheimer's disease (EOAD)
Beyond the preview
Go deeper on TCTR20260903010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260903010.